Zoetis Inc. (NYSE:ZTS) Stock Holdings Trimmed by Dorsey & Whitney Trust CO LLC

Dorsey & Whitney Trust CO LLC lowered its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 13.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,927 shares of the company’s stock after selling 594 shares during the period. Dorsey & Whitney Trust CO LLC’s holdings in Zoetis were worth $640,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the business. Mission Wealth Management LP raised its stake in Zoetis by 2.0% during the 4th quarter. Mission Wealth Management LP now owns 2,938 shares of the company’s stock valued at $479,000 after acquiring an additional 59 shares in the last quarter. Hancock Whitney Corp raised its stake in Zoetis by 0.3% during the 3rd quarter. Hancock Whitney Corp now owns 18,569 shares of the company’s stock valued at $3,628,000 after acquiring an additional 61 shares in the last quarter. Strategy Asset Managers LLC raised its stake in Zoetis by 3.5% during the 3rd quarter. Strategy Asset Managers LLC now owns 1,822 shares of the company’s stock valued at $356,000 after acquiring an additional 62 shares in the last quarter. VeraBank N.A. raised its stake in Zoetis by 4.1% during the 4th quarter. VeraBank N.A. now owns 1,562 shares of the company’s stock valued at $254,000 after acquiring an additional 62 shares in the last quarter. Finally, Procyon Advisors LLC raised its stake in Zoetis by 1.4% during the 4th quarter. Procyon Advisors LLC now owns 4,712 shares of the company’s stock valued at $768,000 after acquiring an additional 63 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the business’s stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the transaction, the executive vice president now owns 16,107 shares in the company, valued at $2,757,196.26. The trade was a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

ZTS has been the topic of a number of research reports. StockNews.com raised Zoetis from a “hold” rating to a “buy” rating in a research note on Friday. Barclays boosted their price objective on Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research note on Friday, February 14th. Stifel Nicolaus dropped their price objective on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Leerink Partners initiated coverage on Zoetis in a research note on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price objective on the stock. Finally, Leerink Partnrs raised Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. One analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Zoetis presently has a consensus rating of “Buy” and an average target price of $215.90.

Zoetis Stock Performance

Shares of ZTS stock opened at $170.34 on Monday. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $200.33. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. The company has a market capitalization of $76.28 billion, a price-to-earnings ratio of 31.14, a P/E/G ratio of 2.78 and a beta of 0.94. The stock’s fifty day simple moving average is $166.72 and its 200-day simple moving average is $176.74.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The business had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion. On average, sell-side analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be paid a $0.50 dividend. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a yield of 1.17%. Zoetis’s dividend payout ratio (DPR) is currently 36.56%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.